The annual result looks good to me. Revenue up 167%, cash position at $14m, market cap currently at $22m. Further growth in revenue happening. P/E ratio at 7.6 - way to low for a growth stock and a Biotech as well. Anything below 10c has to be cheap.
- Forums
- ASX - By Stock
- SIE
- take the opportunity
take the opportunity
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)